Alnylam Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $645.4M | $193.6M | $180.9M | $75.2M | $53.2M | $51.4M | $70.2M | $74.6M |
| Accounts Receivable | $34.0M | $23.3M | $8.3M | $39.9M | $4.2M | $104.0K | $1.5M | $3.5M |
| Inventory | — | — | — | — | — | — | — | — |
| Total Current Assets | $1.76B | $671.9M | $1.11B | $746.4M | $254.0M | $125.6M | $152.0M | $254.1M |
| Property, Plant & Equipment | $181.9M | $114.6M | $27.8M | $21.7M | $16.4M | $19.8M | $14.6M | $18.3M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | $275.0K | $448.0K |
| Total Assets | $1.99B | $1.26B | $1.39B | $1.08B | $420.5M | $287.5M | $281.9M | $393.3M |
| Liabilities | ||||||||
| Accounts Payable | $28.4M | $54.5M | $16.8M | $15.1M | $5.9M | $4.4M | $5.8M | $9.3M |
| Total Current Liabilities | $144.3M | $131.7M | $62.1M | $95.3M | $53.9M | $48.3M | $81.0M | $102.0M |
| Long-Term Debt | — | — | — | — | — | — | — | — |
| Total Liabilities | $228.3M | $342.6M | $121.8M | $143.3M | $150.2M | $153.5M | $163.9M | $235.0M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-2.15B | $-1.66B | $-1.25B | $-956.6M | $-596.2M | $-507.0M | $-401.0M | $-343.3M |
| Total Stockholders' Equity | $1.77B | $920.2M | $1.26B | $936.3M | $270.3M | $134.1M | $118.0M | $158.2M |